A PHASE II STUDY OF TESETAXEL AS FIRST-LINE THERAPY FOR SUBJECTS WITH METASTATIC BREAST CANCER.

Trial Profile

A PHASE II STUDY OF TESETAXEL AS FIRST-LINE THERAPY FOR SUBJECTS WITH METASTATIC BREAST CANCER.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tesetaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 22 May 2012 Results will be presented at ASCO-2012 according to a Genta media release. Results were also reported in the media release.
    • 22 May 2012 Status changed from recruiting to active, no longer recruiting according to a Genta media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top